by Kupffer cells in the liver, were reduced by EndoS. Our data indicate that EndoS is a potential therapeutic agent that might be evaluated as an alternative to current treatment regimens against antibody mediated destruction of RBC.
INTRODUCTION
The presence and pathogenicity of autoantibodies directed against red blood cells (RBC) have been extensively investigated and implicated in a number of autoimmune diseases such as autoimmune hemolytic anemia (AIHA) 1 and systemic lupus erythematosus (SLE) 2 . The RBC surface contains many epitopes recognizable by allo-and autoantibodies, including the more than 300 blood group antigens located on glycoproteins and glycolipids but also non-polymorphic/non-blood group protein structures 3 . The most common targets of pathogenic RBC autoantibodies are epitopes on the Rh protein, encoded by two homologous genes on chromosome 1, RHD and
RHCE

4
. More than half of all autoantibody specificities in patients with AIHA of the common so-called warm type include IgG antibodies against these Rh epitopes, which are consequently often used to model AIHA experimentally.
Human antibodies against RhD (anti-D) or rabbit antibodies against human RBC (anti-RBC) can result in accelerated phagocytosis and removal of RBC from the circulation by monocytes/macrophages in the spleen and liver 5, 6 . Fcγ receptor (FcγR)-mediated erythrophagocytosis, in addition to other IgG effector functions as activated complement, oxidative burst and cytokine production by FcγR expressing effectors cells, play an essential role in shortened RBC survival [7] [8] [9] [10] [11] . The ability of normal human monocytes to bind and phagocyte IgG-sensitized RBC via FcγR, and mediate immune RBC destruction, is highly related to the glycosylation status of the Fc domain on the anti-RBC antibodies [12] [13] [14] [15] [16] [17] .
Endoglycosidase S (EndoS) is secreted by Streptococcus pyogenes and has a specific endoglycosidase activity on native IgG by hydrolyzing the conserved asparagine-linked glycans on the heavy chains of IgG 18, 19 . EndoS is the first known bacterial enzyme with a unique specificity for native IgG. EndoS affects the For personal use only. on October 3, 2017 . by guest www.bloodjournal.org From 
MATERIALS and METHODS
Human blood donors and preparation of plasma, red cells and monocytes.
For RBC sensitization, blood was drawn from healthy Rh-positive individuals and collected in heparin-containing tubes. After centrifugation at 1100 x g for 10 minutes, plasma and buffy coat aspiration, RBC were washed 5 times with 10 volumes of phosphate buffered saline (PBS): 10 mM phosphate buffer, pH 7.4, 120 mM NaCl, 3 mM KCl. RBC, 1 ml of 5% suspension, were incubated with 100 μl commercial human anti-D, 0.1 mg/ml in PBS for 1 hour at 37°C with following washes in PBS.
For sensitization of RBC with rabbit IgG 300 μl of 5% RBC suspension were incubated with equal volume of rabbit IgG against human RBC (anti-RBC), diluted to 0.1 mg/ml. This IgG fraction antibody was purified from antiserum by a multi-step process including delipidation, salt fractionation, ion exchange chromatography followed by dialysis against 0.02 M potassium phosphate, 0.15 M sodium chloride, pH 7.2. Peripheral blood monocytes were separated from heparinized human whole blood from healthy volunteers using Ficoll-Paque Plus (Amersham Biosciences, Uppsala, Sweden) according to instructions provided by the manufacturer. After isolation, the monocytes were washed 3 times with PBS and finally resuspended in RPMI-1640 medium containing 10% fetal calf serum (FCS) to the concentration 4 to 6 x 10 6 cells/ml. The human monocytic cell line THP-1 (ATCC, Rockville, MD, USA) was cultured in RPMI-1640 medium supplemented with 10% FCS and 10 μg/ml gentamycin at 37°C in an atmosphere containing 5% CO 2 and 95% humidity.
Nunclon flasks (Nunc, Roskilde, Denmark) for cell culture were used.
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RBC-labeling with fluorescein isothiocyanate (FITC)
In some cases FITC-labeled RBC were used for sensitization with anti-D (Rhesonativ, 0.1 mg/ml) and subsequent phagocytosis experiments. FITC-labeling of RBC was performed according to the earlier description 23 . Briefly, RBC were resuspended to 1 Subsequently, cells were washed five times with PBS and centrifuging at 400 x g, and non-ingested RBC were lyzed with 0.5 ml distilled water for 20 seconds followed by two washes in PBS. This treatment has been described to entirely lyze adherent RBC without influencing the integrity of monocytes 25 . Finally, the cells were dissolved in 500 μl 0.1 M NaOH containing 0.05% (vol/vol) Triton X-100 and the concentration of ingested hemoglobin (RBC) was measured using 2,7 diaminofluorene. C1q uptake studies. C1q binding to sensitized RBC were analyzed as described previously 28 with small modifications. Briefly, blood was collected in EDTA-tubes.
Monocyte monolayer assay (MMA)
Three hundred µl of 5% RBC suspension in isotonic Veronal-buffered saline containing 0.1% gelatin, 0.15 mM CaCl 2 and 1 mM MgCl 2 (GVBS 2+ ) were incubated with an equal volume of rabbit anti-RBC (10 μg/ml), with or without pre-treatment of antibodies with EndoS, or buffer for 30 minutes at 37°C. After two washes in GVBS 2+ RBC, pellets were resuspended in 250 μl human serum and were incubated at 30°C for 15 minutes. After washing of pellets, FITC-conjugated anti-human C1q was added and incubated for 60 minutes at room temperature. After three washes of cell pellets, fluorescence intensity was measured using a Wallac 1420 Multilabel
Counter.
Experimental AIHA. Animals studies described in this manuscript were approved by the Ethical Committee for Animal Experimentation at the Faculty of Medicine of the University of Geneva in Switzerland. AIHA was induced in two month-old BALB/c mice by a single i.v. injection of purified murine 34-3C anti-RBC monoclonal autoantibody as described previously 29 . The hybridoma secreting the 34-3C IgG2a
anti-RBC monoclonal autoantibody was derived from unmanipulated NZB mice 30 and the generation of IgG1 and IgG2b subclass-switch variants was described previously 29 . 24h after the injection of anti-RBC mAb, 20 μg of EndoS were i.v.
administered. Blood samples were collected by orbital sinus puncture into heparinized microhematocrit tubes, and hematocrit values were directly determined after centrifugation. The deposition of C1q and C3 on RBC was detected 24 h after injection of EndoS or PBS in mice pretreated with 34-3C anti-RBC mAb by a flow cytometry assay, using biotinylated goat anti-mouse C1q 31 or goat anti-mouse C3
followed by PE-conjugated streptavidin, as previously described. The injection of mAb was controlled by assessing the level of antibody opsonization of RBC by using biotinylated rat anti-mouse k chain mAb 32 . Livers, obtained 8 days after injection of mAb, were processed for histological examination, and the extent of in vivo RBC destruction by Kupffer cell-mediated phagocytosis was determined by iron staining using Perls Prussian blue stain, which is widely used to demonstrate ferric iron in tissues. No counterstaining was performed. 
Statistics. Student t-tests
RESULTS
Treatment of anti-D with EndoS does not affect the binding of anti-D to RBC
We Lens culinaris agglutinin (LCA) lectin using ELISA (Fig. 1a,b) . Furthermore, the results showed that the treatment of anti-D with EndoS did not affect the antigen recognition by this antibody and the amount of RBC-bound IgG was not influenced by EndoS treatment (Fig. 1a,c) .
EndoS inhibits phagocytosis and adherence of sensitized RBC by monocytes
The effect(s) of EndoS on phagocytosis of anti-D sensitized RBC by monocytes was analyzed using MMA. Monolayers of monocytes were cultured on slides and RBC pre-sensitized with anti-D, were added to the monolayers. The degree of phagocytosis was determined using light microscopy and expressed as the number of monocytes with adherent/phagocytosed RBC by analyzing 100 monocytes. As expected the phagocytosis of anti-D-sensitized RBC was significantly greater than non-sensitized RBC and was efficiently eliminated by pre-treatment of anti-D with EndoS (p < (Fig. 2a) . The number of "rosettes" (3 or more RBC attached to each monocyte) was greater for anti-D sensitized RBC than for RBC sensitized with anti-D pre-treated with EndoS (Fig. 2b) (Fig. 2c) . Accumulation of hemoglobin in monocytes could also be visualized macroscopically with red colored resuspended monocytes after incubation with sensitized RBC, compared to colorless monocytes when EndoS pre-treated anti-D was used for sensitization of RBC (Fig 2d) . To further confirm this observation, (Fig. 2e) . This clearly shows that the treatment of anti-D 
EndoS inhibits oxygen metabolite production by monocytes induced by sensitized RBC
In an attempt to further elucidate the effects of EndoS on monocyte-driven cell cytotoxicity to sensitized RBC, we measured the release of oxygen metabolites from monocytes using a chemiluminescence test (CLT). RBC were opsonized with immune plasma with high titers of anti-D from three individuals. Monocyte responses to sensitized RBC were compared with their response to unsensitized cells and expressed as a ratio (opsonic index). RBC incubated with immune plasma gave positive results in CLT with opsonic index 2.5. In contrast, monocyte responses to RBC incubated with immune plasma pre-treated with EndoS were significantly decreased (plasma 1, p < 0.07, plasma 2, p < 0.02, plasma 3, p < 0.015) and in some cases even below the control plasma (Fig. 3) . These results suggest that treatment of immune plasma with EndoS abrogates in vitro metabolic oxidative responses by monocytes.
EndoS inhibits IL-8 secretion from monocytes induced by sensitized RBC
It has been reported that interleukin-8 (IL-8) besides being produced by monocytes in response to lipopolysaccharide, tumor necrosis factor-α or IL-1, is implicated as an indicator of RBC incompatibility and mediator of the pathological events in hemolysis in for example hemolytic transfusion reactions [33] [34] [35] . Therefore, we found it relevant to establish the role of EndoS regarding the in vitro response of monocytes Having future experiments, involving not only pre-treatment of antibody but also a direct addition of EndoS to blood, in mind we found it of importance to exclude any direct effects of EndoS on IL-8. EndoS was therefore incubated with purified IL-8 and analyzed by SDS-PAGE. No changes in the IL-8 band intensity were visible confirming that there were no direct activity of EndoS on IL-8 (Fig. 4, inset) .
Furthermore, to investigate if the results described here were independent of any cytotoxic effect of EndoS, a viability test was performed by using Annexin V and propidium iodide staining, detecting apoptotic and necrotic cells respectively. For EndoS treated monocytes, 0.68% of cells were stained for Annexin V and 1.14% for propidium iodide and these results were comparable with results obtained for untreated monocytes, 0.82% and 1.25% of cells respectively. These results demonstrate that EndoS does not have any direct cytotoxic effects on monocytes.
EndoS inhibits hemolysis of sensitized RBC and prevents binding of C1q to IgGsensitized RBC
Human anti-D antibodies of IgG isotype do not generally activate the complement pathway and RBC coated with these antibodies are preferentially cleared by For personal use only. on October 3, 2017. by guest www.bloodjournal.org From mononuclear phagocytic cells via FcγRs. Therefore, in an attempt to study the antihemolytic effects of EndoS by analyzing complement activation of sensitized RBC, a polyclonal rabbit anti-human RBC was used. EndoS hydrolysis of IgG glycans was confirmed by Western blot and lectin ELISA (Fig. 5a,b) and IgG on sensitized RBC was detected by ELISA (Fig. 5a,c) . The rabbit anti-human RBC with and without treatment with EndoS was added to whole blood and after pelleting of the blood cells, the supernatants were analyzed for hemoglobin using 2,7 diaminofluorene. This revealed an expected increase in hemoglobin concentration using sensitized RBC. In contrast, only negligible 2,7 diaminofluorene activity was seen using EndoS-treated anti-RBC, indicating inhibition of complement mediated lysis of RBC (p < 0.0001) (Fig. 6a) . We next aimed to elucidate whether a simultaneous addition of EndoS and antibody to blood, without the previous treatment of antibody with EndoS, could have a similar anti-hemolytic effect. Indeed, it was clearly shown that pre-treatment of antibody by EndoS is not a prerequisite for inhibition of hemolysis and that a direct addition of EndoS to blood was sufficient to exclude hemolytic effect of anti-RBC (p < 0.0001) (Fig. 6a (1) ). EndoS by itself did not have any effect on hemolysis (p < 0.0001) ( Fig. 6a  (2) ). Furthermore, addition of increasing concentrations of anti-RBC IgG to whole blood caused a strong agglutination reaction as expected. Remarkably, addition of EndoS-treated antibody abrogated this effect (Fig. 6b) Pellets of sensitized RBC were then incubated with human serum for 15 minutes at 30°C followed by detection of complement factor C1q uptake using FITC-labeled anti-human C1q. Indeed, there was significantly decreased fluorescence intensity in the samples containing RBC sensitized with EndoS-treated anti-RBC (p < 0.001) when compared with RBC treated with native antibody. These results indicated an inability of C1q to bind to these RBC (Fig. 6c) providing further evidence for the complement inhibitory/anti-hemolytic properties of EndoS.
EndoS inhibits AIHA in vivo
To elucidate the in vivo effects of EndoS in the development of antibody mediated hemolysis/anemia, BALB/c mice were injected with 34-3C IgG2b anti-RBC monoclonal antibodies (mAb), a model used for studying the development of AIHA resulting from FcγR-and complement receptor mediated erythrophagocytosis by Kupffer cells in the liver 36 . Injection of anti-RBC mAb induced a significant drop in hematocrit values at day 1 (42.7 ± 2.0%) as compared with those before the injection (48.1 ± 1.3%, p < 0.001) (Fig. 7a) . Then, mice were divided into two groups with subsequent administration of EndoS to one of the groups. At day 4, hematocrit values in EndoS-treated mice were 33.7 ± 3.1% and significantly higher than hematocrits of the mice in the control group (26.8 ± 2.0%; p < 0.01) (Fig. 7a) . Furthermore, the deposition of C1q and C3 on RBC was analyzed by flow cytometry 24 hours after injection of EndoS. This revealed a significant decrease in C1q and C3 deposition on (Fig. 7b) . Additionally, the effect of EndoS on 34-3C IgG1 and IgG2a class-switch variants was also determined. We EndoS might therefore be an attractive alternative to be used solely or in combination with already present alternatives.
RBC in mice treated with EndoS compared with PBS-treated mice (mean
Bacterial glycosidases have been used previously to modify human molecules for potential medical use. For instance, conversion of the blood-group-specific carbohydrate residues found on group A, B and AB RBC to universal blood that types as group O was recently made possible by the discovery of a novel family of exoglycosidases. These are now being evaluated for applications in transfusion medicine 38, 39 . However, the benefit of EndoS action is the specific activity against IgG, apparently without affecting the RBC surface itself. Other endoglycosidases such as EndoF 1-3 from Elisabethkingia meningoseptica or EndoE from Enterococcus faecalis have activity on a broad range of glycoproteins 40, 41 . Thus, EndoS is the only known endoglycosidase that exclusively hydrolyzes the glycans of IgG 22, 24 . This could be exploited as a novel therapeutic modality for pathological conditions involving antibodies directed towards RBC. An additional benefit of EndoS, that makes this enzyme reasonable for the future administration as a therapeutic agent, is that at therapeutic levels in mice no significant IgG response against EndoS could be observed 42 .
EndoS counteracts the toxic effects of anti-D by decreasing the release of IL-8, a cytokine associated with inflammation 34, 43 . This is in agreement with observation EndoS has an inhibitory effect on autoimmune inflammation in mice 42 . Thus, it can be reasonable to suggest that 15 mg EndoS injected into the circulation of humans is enough to completely hydrolyze the whole pool of IgG. This could be an attractive alternative to IVIG therapy of AIHA where routinely two g/kg/month is used.
Immunogenicity of EndoS could be a potential problem, but despite repeated injections and high antibody titers against EndoS in rabbits, the enzymatic activity is not inhibited 22 
EndoS is worth
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From special attention when evaluating therapeutic advantages since it has a dual function such as an inhibitor of both platelet and RBC elimination.
In conclusion, the results presented here establish that EndoS treatment should be considered as future therapy not only for AIHA but also for other pathological conditions characterized by an abnormal removal of IgG-opsonized RBC by macrophages. 
